In medicine, we like to believe that progress is linear. That once a patient stabilizes, regains lost skills, and returns to work, the hardest part is behind them. But in addiction care, stability is fragile because the systems supporting patients are weak.
Recently, I sat with a patient who has done everything we ask of people in recovery. She has been abstinent for years. She attends visits. Her urine drug screens are consistently appropriate. She works. She parents. She plans for the future. And yet, halfway through our appointment, her voice changed, not when we discussed cravings or trauma, but when she told me her insurance premium was about to triple.
From $40 a month to $138.
That number may not register as catastrophic to policymakers or insurers. But to someone living paycheck to paycheck, it is not an “adjustment.” It is a threat. A threat to medication continuity. To housing stability. To everything recovery depends on.
This is the part of addiction medicine we rarely name out loud: Relapse is often engineered far upstream from individual choice.
Insurance changes, premium hikes, formulary shifts, and prior authorization barriers are routinely framed as administrative necessities. But for patients on medications for opioid use disorder, these changes function as clinical events. They interrupt care, increase stress, and force impossible decisions: rent or medication, groceries or copays, therapy or utilities.
We know, with overwhelming evidence, that medications like buprenorphine reduce overdose risk and mortality. We also know that treatment interruption, even brief, raises the risk of return to use. Yet we continue to design insurance systems that treat these medications as optional, negotiable, or disposable.
The result is a quiet relapse engine.
It doesn’t look like the dramatic crises we’re trained to respond to. It looks like a missed refill because coverage lapsed. A delayed prior authorization that stretches into withdrawal. A decision to stop therapy because copays became unaffordable.
By the time relapse occurs, we often document it as a failure of adherence or engagement. Rarely do we document the role of policy.
What makes this moment particularly dangerous is scale. Recent insurance changes — across Medicaid programs, employer-based plans, and marketplace policies — mean that many more patients will soon face similar disruptions. People who have been stable for years are suddenly re-exposed to risk, not because their disease worsened, but because coverage did.
This is not an abstract ethical concern. Every barrier to treatment increases overdose risk. Every forced interruption erodes trust. Every “temporary” gap has permanent consequences for some patients.
Clinicians feel this tension acutely. We are asked to practice evidence-based medicine inside systems that routinely contradict evidence. We counsel patients to prioritize their health, knowing that the cost may be financial ruin. We celebrate recovery milestones while watching policy quietly undermine them.
If we are serious about addressing the overdose crisis, continuity of care cannot be optional. Insurance stability is not ancillary to treatment. It is treatment. Protecting access to medications for opioid use disorder is as essential as protecting access to insulin or anticoagulation. Anything less is not cost-saving; it is cost-shifting, from insurers to emergency departments, families, and morgues.
The real cost of these insurance changes will not appear on balance sheets. It will appear in missed refills, strained households, silent relapses, and deaths that could have been prevented. I hope my patient will be OK. But her insurance has made it less likely.
Recovery is not just an individual achievement. It is a collective responsibility. And right now, our systems are failing the very people they claim to support.
If we continue to ignore that reality, we already know the outcome. And we’re choosing it.
John Fomeche is an addiction medicine fellow at Yale University.
